(S)-2-(3-methylpyrrolidin-1-yl)ethanol | 831197-10-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (S)-2-(3-methylpyrrolidin-1-yl)ethanol
• 英文别名: 2-[(3S)-3-methylpyrrolidin-1-yl]ethanol
• CAS: 831197-10-5
• 化学式: C₇H₁₅NO
• 分子量: 129.202
• InChiKey: ZOTVJESZONIGGS-ZETCQYMHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (S)-2-(3-methylpyrrolidin-1-yl)ethanol 在 钯 偶氮二甲酸二异丙酯 、 四丁基氟化铵 、 甲酸铵 、 溶剂黄146 、 三苯基膦 作用下， 以 四氢呋喃 、 乙醇 、 水 、 乙酸乙酯 为溶剂， 生成 (2S,3R)-3-(4-Hydroxy-phenyl)-2-{4-[2-((S)-3-methyl-pyrrolidin-1-yl)-ethoxy]-phenyl}-2,3-dihydro-benzo[1,4]oxathiin-6-ol
  参考文献：
  名称：

  Estrogen receptor ligands. Part 9: Dihydrobenzoxathiin SERAMs with alkyl substituted pyrrolidine side chains and linkers

  摘要：

  A series of dihydrobenzoxathiin SERAMs with alkylated pyrrolidine side chains or alkylated linkers was prepared. Minor modifications in the side chain or linker resulted in significant effects on biological activity, especially in uterine tissue.

  DOI：

  10.1016/j.bmcl.2004.10.036
• 作为产物：
  描述：

  (S)-methylsuccinic anhydride 在 lithium aluminium tetrahydride 、 三乙胺 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 反应 38.0h， 生成 (S)-2-(3-methylpyrrolidin-1-yl)ethanol
  参考文献：
  名称：

  Estrogen receptor ligands. Part 9: Dihydrobenzoxathiin SERAMs with alkyl substituted pyrrolidine side chains and linkers

  摘要：

  A series of dihydrobenzoxathiin SERAMs with alkylated pyrrolidine side chains or alkylated linkers was prepared. Minor modifications in the side chain or linker resulted in significant effects on biological activity, especially in uterine tissue.

  DOI：

  10.1016/j.bmcl.2004.10.036

文献信息

• Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer
  作者：Johnny Nagasawa、Steven Govek、Mehmet Kahraman、Andiliy Lai、Celine Bonnefous、Karensa Douglas、John Sensintaffar、Nhin Lu、KyoungJin Lee、Anna Aparicio、Josh Kaufman、Jing Qian、Gang Shao、Rene Prudente、James D. Joseph、Beatrice Darimont、Daniel Brigham、Kate Maheu、Richard Heyman、Peter J. Rix、Jeffrey H. Hager、Nicholas D. Smith

  DOI：10.1021/acs.jmedchem.8b00921

  日期：2018.9.13

  antihormonal agents. However, fulvestrant must be administered by intramuscular injections that limit its efficacy. We describe the optimization of ER-α degradation efficacy of a chromene series of ER modulators resulting in highly potent and efficacious SERDs such as 14n. When examined in a xenograft model of tamoxifen-resistant breast cancer, 14n (ER-α degradation efficacy = 91%) demonstrated robust activity

  大约75％的乳腺癌是雌激素受体α（ER-α）阳性，女性通常最初对他莫昔芬和芳香酶抑制剂等抗激素疗法反应良好，但常常会出现耐药性。Fulvestrant是一种基于类固醇的选择性雌激素受体降解剂（SERD），可拮抗和降解ER-α，并且在抗激素药物治疗的患者中显示出一定的活性。然而，氟维司群必须通过肌内注射来限制其功效。我们描述了色烯系列ER调节剂的ER-α降解功效的优化，可导致高效和高效的SERD，例如14n。在耐他莫昔芬的异种移植模型中检查时，14n（ER-α降解功效= 91％）表现出强劲的活性，而尽管口服量较高，但15克（ER-α降解功效= 82％）基本上没有活性。该结果表明，在MCF-7细胞系中优化ER-α降解功效可导致化合物在源自MCF-7背景的他莫昔芬抗性乳腺癌模型中具有强大的作用。
• SUBSTITUTED HETEROCYCLIC COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS
  申请人：Dr. Reddy's Laboratories Ltd.

  公开号：US20150005280A1

  公开（公告）日：2015-01-01

  The present application relates to a series of substituted pyrazolo[1,5-a]pyridine compounds, their use as tropomyosin receptor kinase (Trk) family protein kinase inhibitors, method of making and pharmaceutical compositions comprising such compounds.

  本申请涉及一系列取代吡唑并[1,5-a]吡啶化合物，其作为肌浆蛋白受体激酶（Trk）家族蛋白激酶抑制剂的用途，制备方法以及包含这些化合物的药物组合物。
• Pyrimidines as PLK inhibitors
  申请人：STADTMUELLER Heinz

  公开号：US20110086842A1

  公开（公告）日：2011-04-14

  The present invention encompasses compounds of general formula (1), wherein A, W, X, Y, Z, Ra, Rb, Rc, R1 and R3 are defined as in claim 1 , which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.

  本发明涵盖了一般式（1）的化合物，其中A、W、X、Y、Z、Ra、Rb、Rc、R1和R3如权利要求1所定义，适用于治疗以细胞过度或异常增殖为特征的疾病，并且用于制备具有上述特性的药物组合物。
• Estrogen receptor modulators and uses thereof
  申请人：Kahraman Mehmet

  公开号：US08703810B2

  公开（公告）日：2014-04-22

  Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

  本文描述的是雌激素受体调节剂化合物。还描述了包含所述化合物的药物组合物和药物，以及使用这些雌激素受体调节剂，单独或与其他化合物联合使用，治疗雌激素受体介导或依赖的疾病或病症的方法。
• ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
  申请人：Kahraman Mehmet

  公开号：US20130116232A1

  公开（公告）日：2013-05-09

  Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

  本文描述的是雌激素受体调节剂化合物。还描述了包括本文所述化合物的制药组合物和药物，以及使用这些雌激素受体调节剂，单独或与其他化合物联合使用，治疗介导或依赖于雌激素受体的疾病或病况的方法。